Cardiovascular mortality after intensive LDL-Cholesterol lowering: Does baseline LDL-Cholesterol really matter?

Safi U. Khan a, Erin D. Michos b,∗

a Department of Medicine, West Virginia University, Morgantown, WV, USA
b The Ciccarone Center for the Prevention of Cardiovascular Disease, Johns Hopkins School of Medicine, Baltimore, MD, USA

ARTICLE INFO

Keywords:
LDL Cholesterol
Lipid lowering
Cardiovascular mortality
Meta-analysis

ABSTRACT

It remains controversial whether reductions in cardiovascular mortality after intensive lowering of low density lipoprotein cholesterol (LDL-C) depend on baseline LDL-C levels. To reassess these findings, in this brief report, we performed an updated literature search through February 2020 and selected randomized controlled trials which reported cardiovascular mortality and major adverse cardiovascular events (MACE) as outcomes. We included 53 randomized controlled trials (329,897 patients) of LDL-C lowering therapies (statin, ezetimibe and PCSK9 inhibitors) and stratified the meta-analysis according to the baseline LDL-C thresholds. Our meta-analysis found that each 38.7 mg/dL (1 mmol/L) lowering in LDL-C reduced the risk of cardiovascular mortality (RR, 0.85; 95% CI, 0.81–0.89), but this varied by baseline LDL-C of those in the trials (P = 0.04 for interaction). The risk reduction in cardiovascular mortality was limited to trials with baseline LDL-C of >100 mg/dL. In contrast, the reduction in MACE was independent of baseline LDL-C levels. These findings were consistent in primary and secondary prevention settings for both outcomes and by sex for MACE. Our results support the professional cholesterol guidelines which recommend achieving a ≥50% reduction in LDL-C from baseline for high-risk patients.

Introduction

Low density lipoprotein cholesterol (LDL-C) is a well-established modifiable risk factor for atherosclerotic cardiovascular disease [1–3]. While current American Heart Association (AHA)/American College of Cardiology (ACC)/Multi-society and European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) cholesterol guidelines suggest different therapeutic goals for LDL-C, both professional guidelines recommend intensive lowering of LDL-C level for secondary prevention and high risk primary prevention [1,2].

The Cholesterol Treatment Trialists’ Collaboration (CTTC) meta-analysis of statin therapy showed a consistent relative risk (RR) reduction in major vascular events per 1 mmol/L (38.7 mg/dL) LDL-C reduction that was independent of baseline LDL-C levels [4]. These findings were also shown in a recent meta-analysis by Wang and colleagues, who concluded that RR reduction in major vascular events per 1 mmol/L reduction in LDL-C was independent of starting LDL-C levels, or other risk factors such as diabetes or chronic kidney disease [5]. Wang et al. abstracted primary endpoints from trials that closely approximated a composite of cardiovascular mortality, myocardial infarction or acute coronary syndrome, stroke and coronary revascularization. Although similar methods have been previously used [6], this approach is not ideal given substantial heterogeneity in the definition of primary endpoint across the trials. Moreover, since the authors did not perform a meta-analysis of the individual components of the primary outcome, the influence of individual cardiovascular endpoints on the results remains uncertain.

The most important issue is the influence of baseline LDL-C on cardiovascular mortality after intensive LDL-C reduction. Navarese et al. reported that intensive LDL-C lowering reduced the risk of major adverse cardiovascular events (MACE), independently of baseline LDL-C [7]. However, cardiovascular mortality benefit was limited to trials with baseline LDL-C >100 mg/dL. Similar findings were noted in another meta-analysis of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors [8].

To reassess these findings, in this brief research report, we performed an updated meta-analysis of the benefits of LDL-C lowering therapy on cardiovascular mortality by baseline LDL-C concentrations. We hypothesized that while MACE reduction per 38.7 mg/dL lowering in LDL-C by LDL-C lowering therapy would be independent of baseline LDL-C levels,
that the cardiovascular mortality risk reduction would be exclusively limited to patients with LDL-C >100 mg/dL. Our secondary hypothesis was that cardiovascular risk reduction in patients >100 mg/dL would be consistent across sex and setting (primary vs secondary prevention).

Methods and results

We performed an updated literature search through 02/02/2020 and selected randomized controlled trials which reported cardiovascular mortality and MACE. We included 53 randomized controlled trials (329,897 patients) of LDL-C lowering therapies (statin, ezetimibe and PCSK9 inhibitors). Data were abstracted on drugs, baseline LDL-C and mean LDL-C reduction achieved in the trial, sex-specific estimates and the type of patients enrolled in trials (primary, secondary or both). Since cardiovascular mortality was not primary endpoint in component trials of this meta-analysis, sex-specific data were only available for MACE. Twenty trials were conducted in secondary prevention setting, 12 trials in primary prevention and 19 trials enrolled mixed cohort. Meta-analysis was stratified according to the baseline LDL-C thresholds [7]. We standardized the analysis to 38.7 mg/dL reduction in LDL-C by taking log summary statistic of each trial and multiplying it by 1/d, where d refers to the mean LDL-C reduction (mg/dL) in the trial [5].

Our meta-analysis showed that each 38.7 mg/dL in LDL-C lowering reduced the risk of cardiovascular mortality [Risk Ratio (RR), 0.85; 95% confidence interval (CI), 0.81–0.89], but this varied by baseline LDL-C of those in the trials. The risk reduction in cardiovascular mortality was limited to trials

![Fig. 1. Relative Risk of Cardiovascular Mortality per 38.7 mg/dL reduction in LDL-C, by baseline LDL-C Concentration Squares represent individual studies, with the size proportional to the weight in the meta-analysis. Diamonds represent pooled results.](image-url)
with baseline LDL-C of >100 mg/dL (P = 0.04 for interaction; Fig. 1). On the other hand, the reduction in MACE was independent of baseline LDL-C levels. Each 38.7 mg/dL lowering in LDL-C reduced the RR of MACE by 0.80 (95% CI, 0.77–0.83), which was consistent in trials with baseline LDL-C <100 mg/dL (0.83, 95% CI, 0.76–0.90), 100–129 mg/dL (0.77, 95% CI, 0.69–0.85), 130–159 mg/dL (0.82, 95% CI, 0.78–0.86) or ≥160 mg/dL (0.78, 95% CI, 0.75–0.82) (P = 0.49 for interaction). Subgroup analysis in trials with baseline LDL-C >100 mg/dL showed that RR reductions in cardiovascular mortality and MACE were consistent across primary or secondary prevention trials, or sex in case of MACE (Table 1).

### Discussion

Reduction in cardiovascular mortality depends on several factors, including large absolute LDL-C reduction, long-term follow-up, high-risk patients, therapeutic efficacy of the drug and minimal or no competing risk or off target effects [6–8]. Therefore, patients starting with a baseline LDL-C >100 mg/dL have a stronger signal for mortality reduction, as they would be expected to have a larger absolute reduction in LDL-C [6–8]. This concept was consistently shown across various clinical trials of lipid lowering therapy. For instance, in earlier PCSK9 inhibitor trials, ODYSSEY LONG TERM and OSLER showed numerically lower mortality rates in participants with baseline LDL-C levels of ~120 mg/dL [9,10]. In the recent ODYSSEY OUTCOMES trial, the absolute risk reduction in primary endpoint was most pronounced in patients with baseline LDL-C >100 mg/dL [11]. There was also a 15% RR reduction in all-cause mortality among patients with recent acute coronary syndrome receiving alirocumab. However, because of pre-specified hierarchical testing of secondary endpoints, the reduction in all-cause mortality was considered a nominal finding in the absence of cardiovascular mortality. Similarly, among trials of statin therapy, the 4S trial showed a 25% RR reduction in all-cause mortality in patients with starting LDL-C level of 188.3 mg/dL [12]. In GREACE, there was 43% RR reduction in patients with baseline LDL-C of 180 mg/dL [13]. Similar findings were noticed in other trials, such as the PROVE-IT TIMI 22, LIPID and HPS trials [14–16].

The findings may also potentially explain the lack of mortality benefit in the FOURIER (baseline LDL-C = 92 mg/dL) and IMPROVE-IT (baseline LDL-C = 93.8 mg/dL) trials, where despite achieving very low levels of LDL-C, evolocumab and ezetimibe (plus statin therapy), respectively, did not reduce the risk of cardiovascular or all-cause death [17,18]. Of note, an important limitation of PCSK9 inhibitor trials in reducing mortality was relatively shorter follow-up duration compared with statin trials. A comparative analysis of CTTC meta-analysis of statin therapy and FOURIER and SPIRE trials showed that the magnitude of cardiovascular risk reduction achieved by PCSK9 inhibitor was similar to what would have been expected up to two years, signaling that beneficial effects of therapy potentiate over time [19,20].

In summary, consistent with prior reports [7,8], we argue that while the effect of intensive LDL-C lowering on a MACE endpoint might be independent of starting LDL-C levels, the mortality benefit is most likely restricted to patients with higher baseline LDL-C levels. These findings refute the impression of CTTC meta-analysis or study by Wang and colleagues, which suggest that patients at lower cardiovascular risk might have similar RR reduction with LDL-C lowering therapies [4,5]. In fact, our results support the professional cholesterol guidelines which recommend achieving a >50% reduction in LDL-C from baseline for high-risk patients.

### Funding

Dr. Michos is supported by the Amato Fund for Women’s Cardiovascular Health Research.

### Declaration of competing interest

No conflicts of interest.

### References

[1] Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACP/ADA/AGS/APHA/ASP/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American heart association task force on clinical practice guidelines. J Am Coll Cardiol 2019;73(24):2885–3500.

[2] Mach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020;41(1):111–88.

[3] Michos ED, McGovry JW, Blumenthal RS. Lipid management for the prevention of atherosclerotic cardiovascular disease. N Engl J Med 2019;381(16):1557–67.

[4] Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010;376(9753):1670–81.

[5] Wang N, Fulcher J, Abeywickrama N, et al. Intensive LDL cholesterol-lowering treatment beyond current recommendations for the prevention of major vascular events: a systematic review and meta-analysis of randomised trials including 327 037 participants. Lancet Diabetes Endocrinol 2020;8(6):36–49.

[6] Silverman MG, Ference BA, Im K, et al. Association between lowering LDL-c and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis. J Am Med Assoc 2016;316(12):1289–97.

[7] Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. J Am Med Assoc 2018;319(15):1566–79.

[8] Khan SU, Riaz H, Rahman H, et al. Association of baseline LDL-C with total and cardiovascular mortality in patients using propionate convertase subtilisin/kinin type 9 inhibitors: a systematic review and meta-analysis. J Clin Lipidol 2019;13(4):538–49.

[9] Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489–99.

[10] Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1500–9.

[11] Schwartz GG, Steg PG, Szarek M, et al. Alirocumab and cardiovascular outcomes after acute coronary syndrome. N Engl J Med 2018;379(22):2097–107.

[12] Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344(8934):1383–9.

[13] Athyros VG, Papageorgiou AA, Mercouris BR, et al. Treatment with atorvastatin to reducing lipids and cardiovascular events. N Engl J Med 2015;372(16):1489–99.

[14] Cannon CP, Braunwald E, McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004;350(15):1495–504.

[15] Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med 1998;339(19):1349–57.

[16] MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002;360(9326):7–22.

[17] Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015;372(25):2387–97.

[18] Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017;376(18):1713–22.

[19] Ference BA, Cannon CP, Landmesser U, Luscher TF, Catapano AL, Ray KK. Reduction of low density lipoprotein-cholesterol and cardiovascular events with proprotein convertase subtilisin/kinin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialsists Collaboration. Eur Heart J 2018;39(27):2540–5.

[20] Khan SU, Khan MU, Valavar S, et al. Association of lowering apolipoprotein B with cardiovascular outcomes across various lipid-lowering therapies: systematic review and meta-analysis of trials. Eur J Prev Cardiol 2019. https://doi.org/10.1177/2047487319871733. 2047487319871733 [Epub ahead of print].

**Table 1**

| Subgroup | Cardiovascular mortality | MACE |
|----------|-------------------------|------|
| Primary  | 0.79 (0.69, 0.90)       | 0.74 (0.69, 0.80) |
| Secondary| 0.86 (0.80, 0.92)       | 0.80 (0.77, 0.83) |
| F-interaction | 0.29               | 0.06 |
| Sex      |                         |      |
| Men      | 0.81 (0.77, 0.86)       |      |
| Women    | 0.85 (0.80, 0.90)       |      |
| F-interaction |                 | 0.28 |